share print

Cell therapy pipeline

We are actively involved in the emergence of regenerative medicine by supporting enhancement of cell-based technologies through our subsidiary Celogos, experts in the restoration of tissue function and muscle regeneration.

We are currently developing two product candidates: CEL – 01, for the treatment of Urinary Incontinence (UI)  and CEL – 02, for the treatment of Fecal Incontinence (FI).

CEL-O1

CEL-01 is a first generation, cell-based product intended for stress Urinary Incontinence (UI) treatment. CEL-01 has been evaluated in two phase II clinical trials with promising results.

 

CEL-02

CEL-02 is indicated for the treatment of Fecal Incontinence (FI); and is currently being evaluated in a phase II clinical trial.

 

The therapeutic cell therapy process
Celogos is a subsidiary of HRA Pharma, which focuses on cell-based technologies. The process involves isolating muscle cells or myoblasts from biopsies of a patient's muscle. These cells are then cultured, frozen, and re-injected into the patient. The myoblasts then develop into mature muscle cells, with the potential to repair the damaged tissue.



closeyou are leaving hra pharma
You are now leaving www.hra-pharma.com and being redirected to an external website which might not be under control of HRA Pharma.
do you want to proceed ?